JAZZ Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals develops and markets specialty pharmaceutical products focused on sleep disorders, oncology, and neuroscience, including treatments for narcolepsy and leukemia. Sector: Healthcare.

Jazz Pharmaceuticals PLC (JAZZ) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On a capital return basis, ROIC is 8.70%, WACC is 5.33%, and the economic spread is 3.36%. On balance, the economic spread is positive but compressed — adequate for value preservation, less convincing for aggressive compounding. Supporting metrics show ROE at -8.63% and ROA at 1.14%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

On valuation, the company registers trailing P/E of 7.87, forward P/E of 7.84, PEG of 0.14. The minimal trailing-to-forward compression implies limited earnings growth expectations are embedded in current prices. The PEG reading suggests the market is pricing growth conservatively — a dynamic that can be favorable if earnings estimates prove accurate. A current ratio of 1.86 suggests the the company have sufficient short-term liquidity without excess. Taken together, the multiple and liquidity picture suggests a company that is priced for a constructive outcome — but where execution against earnings estimates will be the key determinant of whether that price is justified.

Stripping to unit economics, gross margin sits at 89.94%, operating margin at 17.99%, and free cash flow margin at 28.62%. Gross margins are exceptional, reflecting strong pricing power and a defensible cost structure. The operating margin reading is constructive, suggesting management teams are managing overhead costs effectively. The company's free cash flow margin is exceptional, pointing to capital-light businesses with strong reinvestment optionality. Read as a whole, the margin picture suggests a business with strengths in parts but no clear margin dominance end-to-end.

Connecting operational trends with market expectations, TTM revenue growth of 10.09% indicating steady top-line growth at the company level, while the estimated 12-month price change of 16.15%, where consensus targets suggest reasonable upside rather than a step-change rerating. At 0.4%, projected EPS growth is present and positive — not a standout catalyst, but a stabilizing element in the overall forward picture. Operating momentum and analyst expectations are related but distinct — the former is backward-looking by nature, the latter inherently speculative. Against that backdrop, the more durable question is whether operating trends can be sustained long enough for analyst expectations to be validated. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Overall, the fundamentals support a constructive stance — execution remains the key driver of whether the forward case is fully validated.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.